JP2012501332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012501332A5 JP2012501332A5 JP2011525134A JP2011525134A JP2012501332A5 JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5 JP 2011525134 A JP2011525134 A JP 2011525134A JP 2011525134 A JP2011525134 A JP 2011525134A JP 2012501332 A5 JP2012501332 A5 JP 2012501332A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- lyophilized
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 35
- 102000011718 Interleukin-23 Subunit p19 Human genes 0.000 claims description 15
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 claims description 15
- 239000012931 lyophilized formulation Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000007979 citrate buffer Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9232608P | 2008-08-27 | 2008-08-27 | |
| US61/092,326 | 2008-08-27 | ||
| PCT/US2009/054842 WO2010027766A1 (en) | 2008-08-27 | 2009-08-25 | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Division JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012501332A JP2012501332A (ja) | 2012-01-19 |
| JP2012501332A5 true JP2012501332A5 (enExample) | 2012-10-04 |
| JP5931442B2 JP5931442B2 (ja) | 2016-06-08 |
Family
ID=41495339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011525134A Active JP5931442B2 (ja) | 2008-08-27 | 2009-08-25 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015184258A Pending JP2016028086A (ja) | 2008-08-27 | 2015-09-17 | 操作された抗ＩＬ−２３ｐ１９抗体の凍結乾燥製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8263748B2 (enExample) |
| EP (1) | EP2331078B1 (enExample) |
| JP (2) | JP5931442B2 (enExample) |
| CN (1) | CN102202655B (enExample) |
| AU (1) | AU2009288419B2 (enExample) |
| CA (1) | CA2734919C (enExample) |
| MX (1) | MX2011002159A (enExample) |
| WO (1) | WO2010027766A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2012009760A1 (en) * | 2010-07-20 | 2012-01-26 | Cephalon Australia Pty Ltd | Anti-il-23 heterodimer specific antibodies |
| PT2635601T (pt) | 2010-11-04 | 2016-09-27 | Boehringer Ingelheim Int | Anticorpos anti-il-23 |
| IN2014CN03555A (enExample) | 2011-10-25 | 2015-07-03 | Onclave Therapeutics Ltd | |
| EP2798077A2 (en) | 2011-12-31 | 2014-11-05 | Allergan, Inc. | Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A |
| US10316095B2 (en) * | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
| EP4039275A1 (en) | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
| CZ2012829A3 (cs) | 2012-11-23 | 2014-06-11 | Biotechnologický Ústav Av Čr, V.V.I. | Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23 |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP3693007A1 (en) | 2013-03-15 | 2020-08-12 | Amgen, Inc | Methods for treating crohn's disease using an anti-il23 antibody |
| KR20150128858A (ko) | 2013-03-15 | 2015-11-18 | 암젠 인크 | 항-il-23 항체를 사용한 건선의 치료 방법 |
| US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
| EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
| AR102417A1 (es) | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| IL307578A (en) | 2015-02-04 | 2023-12-01 | Boehringer Ingelheim Int | Methods of treating inflammatory diseases |
| HK1258292A1 (zh) | 2015-09-17 | 2019-11-08 | Amgen Inc. | 使用il23途徑生物標誌物預測il23拮抗劑的臨床應答 |
| CA3002761A1 (en) | 2015-11-04 | 2017-05-11 | Astrazeneca Ab | Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases |
| RU2018124603A (ru) | 2015-12-22 | 2020-01-24 | Эмджен Инк. | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 |
| DK3405400T3 (da) | 2016-01-22 | 2020-04-27 | Baxter Int | Fremgangsmåde og maskine til fremstilling af sterilopløsningsproduktposer |
| PL3405161T3 (pl) | 2016-01-22 | 2020-07-13 | Baxter International Inc | Woreczek do wyrobu w postaci roztworu sterylnego |
| US10940185B2 (en) | 2016-12-28 | 2021-03-09 | Jcr Pharmaceuticals Co., Ltd. | Lyophilized preparation |
| CA3060581A1 (en) | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2019300491A1 (en) | 2018-07-13 | 2021-03-04 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
| BR112021008873A8 (pt) | 2018-11-07 | 2023-04-11 | Merck Sharp & Dohme | Formulação |
| AU2019386021B2 (en) | 2018-11-27 | 2024-02-15 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-il-23p19 antibody and uses thereof |
| JP7266108B2 (ja) | 2019-02-18 | 2023-04-27 | イーライ リリー アンド カンパニー | 治療用抗体製剤 |
| WO2020212874A1 (en) * | 2019-04-15 | 2020-10-22 | Sun Pharma Global Fze | Methods for treatment of subjects with psoriatic arthritis |
| US20210070852A1 (en) * | 2019-09-09 | 2021-03-11 | Boehringer Ingelheim International Gmbh | Anti-IL-23p19 Antibody Formulations |
| GB202107153D0 (en) * | 2021-05-19 | 2021-06-30 | UCB Biopharma SRL | Method for filling vials containing liquid drug products |
| CN115785267B (zh) * | 2021-09-10 | 2023-12-15 | 三优生物医药(上海)有限公司 | 一种靶向IL-23p19的抗体或其抗原结合片段及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DK2130554T3 (da) | 1999-02-22 | 2012-12-03 | Univ Connecticut | Albuminfrie faktor VIII-præparater |
| US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
| WO2004071439A2 (en) | 2003-02-10 | 2004-08-26 | Elan Pharmaceuticals, Inc. | Immunoglobulin formulation and method of preparation thereof |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| JP4762717B2 (ja) * | 2003-10-09 | 2011-08-31 | 中外製薬株式会社 | ＩｇＭ高濃度安定化溶液 |
| CN101287761A (zh) | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
| EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| WO2007024846A2 (en) | 2005-08-25 | 2007-03-01 | Eli Lilly And Company | Anit-il-23 antibiodies |
| SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
| JP5193881B2 (ja) | 2005-12-29 | 2013-05-08 | セントカー・インコーポレーテツド | ヒト抗ｉｌ−２３抗体、組成物、方法および用途 |
| AU2007223903B2 (en) * | 2006-03-06 | 2013-09-05 | Medimmune, Llc | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| AU2007260787A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc | IL-17 and IL-23 antagonists and methods of using the same |
| MX2009007570A (es) * | 2007-01-16 | 2009-07-22 | Abbott Lab | Metodos para tratar la psoriasis. |
| BRPI0807710B1 (pt) | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
| US20100111966A1 (en) | 2007-02-23 | 2010-05-06 | Schering Corporation | Engineered anti-il-23p19 antibodies |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
-
2009
- 2009-08-25 WO PCT/US2009/054842 patent/WO2010027766A1/en not_active Ceased
- 2009-08-25 US US13/061,076 patent/US8263748B2/en active Active
- 2009-08-25 JP JP2011525134A patent/JP5931442B2/ja active Active
- 2009-08-25 AU AU2009288419A patent/AU2009288419B2/en active Active
- 2009-08-25 CA CA2734919A patent/CA2734919C/en active Active
- 2009-08-25 EP EP09791868A patent/EP2331078B1/en active Active
- 2009-08-25 CN CN2009801428023A patent/CN102202655B/zh active Active
- 2009-08-25 MX MX2011002159A patent/MX2011002159A/es active IP Right Grant
-
2015
- 2015-09-17 JP JP2015184258A patent/JP2016028086A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012501332A5 (enExample) | ||
| Tai et al. | A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection | |
| JP7528249B2 (ja) | Ｃｏｖｉｄ－１９に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法 | |
| Sun et al. | Thermal stability of self-assembled peptide vaccine materials | |
| Huleatt et al. | A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity | |
| US20180071389A1 (en) | Monoclonal Antibodies for Ebola and Marburg Viruses | |
| US20230181730A1 (en) | Methods of treating infections | |
| BR112021004193A2 (pt) | vacinas pneumocócicas multivalentes | |
| JP2016534052A5 (enExample) | ||
| IL274846B2 (en) | Formulation for anti-alpha 4 antibody in cell 7 | |
| Nguyen et al. | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents | |
| US11406704B2 (en) | Adjuvants | |
| KR20130114210A (ko) | 스타필로코커스 아우레우스 항원의 안정한 면역원성 조성물 | |
| JPS58213723A (ja) | 口蹄疫ウイルス抗原の特異性を有する小型ペプチド | |
| Stinson et al. | Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine | |
| Demircan et al. | Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response | |
| KR20210088535A (ko) | 폐렴구균 융합 단백질 백신 | |
| TWI615158B (zh) | 多肽之調配物 | |
| Fertig et al. | The atomic portrait of SARS‐CoV‐2 as captured by cryo‐electron microscopy | |
| Gamvrellis et al. | Characterisation of local immune responses induced by a novel nano-particle based carrier-adjuvant in sheep | |
| US20230210980A1 (en) | Chimeric adenoviral vectors | |
| KR20230135598A (ko) | 안정한 코로나바이러스 단백질 및 그의 백신 조성물 | |
| US20230233667A1 (en) | Coronavirus vaccine | |
| JP2022525431A (ja) | 抗原性多量体呼吸器合胞体ウイルスポリペプチド | |
| Mittal et al. | Enhanced protective efficacy of a novel, thermostable, RBD-S2 vaccine formulation against SARS-CoV-2 and its variants |